Lipid nanoparticles have emerged as a versatile and effective platform for drug delivery, offering significant advantages such as biocompatibility, scalability, and the ability to encapsulate diverse therapeutic agents including nucleic acids, proteins, and small-molecule drugs. This review comprehensively explores engineering strategies for enhancing drug encapsulation efficiency and achieving controlled release within LNPs. Key formulation components such as ionizable and PEGylated lipids, along with lipid matrix design, play pivotal roles in optimizing nanoparticle stability, payload capacity, and release kinetics. Advances in fabrication methods including microfluidics and solvent mixing techniques have enabled reproducible production of high-quality LNPs tailored for specific therapeutic applications. The critical role of engineered LNPs is exemplified by their success in RNA therapeutics, notably COVID-19 mRNA vaccines, and expanding applications in cancer therapy and protein delivery. The review also highlights challenges like balancing stability and drug loading, minimizing toxicity, and scaling up manufacturing, alongside emerging solutions. Future perspectives emphasize the development of novel lipid materials, hybrid nanocarriers, and integration with personalized medicine and gene editing. These advances position LNPs as a cornerstone for next-generation nanomedicine platforms aimed at safe, efficient, and targeted delivery for a broad spectrum of diseases. The aim of this review is to comprehensively examine the engineering principles and formulation strategies employed to enhance drug encapsulation efficiency and achieve controlled release in lipid nanoparticles.
| Published in | American Journal of Polymer Science and Technology (Volume 11, Issue 2) |
| DOI | 10.11648/j.ajpst.20251102.11 |
| Page(s) | 15-23 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Lipid Nanoparticles, Drug Encapsulation, Controlled Release, Ionizable Lipids, PEGylated Lipids, Solid Lipid Nanoparticles, Nanostructured Lipid Carriers
| [1] | H. Q. Truong and F. Meng. Unlocking the full therapeutic potential of lipid nanoparticles through extrahepatic delivery, Nano Res., vol. 18, no. 5, pp. 1-15, 2025. |
| [2] | M. Mehta, T. A. Bui, X. Yang, Y. Aksoy, E. M. Goldys, and W. Deng. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development, ACS Mater. Au, vol. 3, no. 6, pp. 600-619, 2023. |
| [3] | G. Son, J. Song, J. C. Park, H. N. Kim, and H. Kim. Fusogenic lipid nanoparticles for rapid delivery of large therapeutic molecules to exosomes, Nat. Commun., vol. 16, no. 1, pp. 1-15, 2025. |
| [4] | C. R. Thorn et al. The journey of a lifetime development of Pfizer’s COVID-19 vaccine, Current opinion in Biotechnology, sciences direct, 2022, 78: 102803. |
| [5] | B. Wilson and K. Mukundan. Lipid nanoparticles in the development of mRNA vaccines for COVID-19, Journal of Drug Delivery Science and Technology, 74 (2022) 103553. |
| [6] | H. Tanaka et al. A Post-Encapsulation Method for the Preparation of mRNA-LNPs via the Nucleic Acid-Bridged Fusion of mRNA-Free LNPs, Nano Lett., vol. 25, no. 16, pp. 6445-6453, 2025. |
| [7] | H. N. Jung, S. Y. Lee, S. Lee, H. Youn, and H. J. Im. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging, Theranostics, vol. 12, no. 17, pp. 7509-7531, 2022. |
| [8] | S. Li et al. Payload distribution and capacity of mRNA lipid nanoparticles, Nat. Commun., vol. 13, no. 1, 2022. |
| [9] | R. Zwolsman, Y. B. Darwish, E. Kluza, and R. van der Meel. Engineering Lipid Nanoparticles for mRNA Immunotherapy, Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology, vol. 17, no. 2, 2025. |
| [10] | S. Karmaker, P. D. Rosales, B. Tirumuruhan, A. Viravalli, and N. Boehnke. More than a delivery system: the evolving role of lipid-based nanoparticles,” Nanoscale, vol. 17, no. 19, pp. 11864-11893, 2025. |
| [11] | X. Hou, T. Zaks, R. Langer, and Y. Dong. Lipid nanoparticles for mRNA delivery, Nat. Rev. Mater., vol. 6, no. 12, pp. 1078-1094, 2021. |
| [12] | L. Xu, X. Wang, Y. Liu, G. Yang, R. J. Falconer, and C. X. Zhao. Lipid Nanoparticles for Drug Delivery, Adv. NanoBiomed Res., vol. 2, no. 2, 2022. |
| [13] | D. L. Pink et al. On the Structure of Solid Lipid Nanoparticles, Small, vol. 15, no. 45, pp. 1-10, 2019. |
| [14] | Y. Seo et al. Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications, Pharmaceutics, vol. 15, no. 3, pp. 1-22, 2023. |
| [15] | N. Dhiman, R. Awasthi, B. Sharma, H. Kharkwal, and G. T. Kulkarni. Lipid Nanoparticles as Carriers for Bioactive Delivery, Front. Chem., vol. 9, 2021. |
| [16] | S. Pandey, F. Shaikh, A. Gupta, P. Tripathi, and J. S. Yadav. A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery, Adv. Pharm. Bull., vol. 12, no. 1, pp. 17-33, 2022. |
| [17] | A. C. Groo, N. Matougui, A. Umerska, and P. Saulnier. Reverse micelle-lipid nanocapsules: A novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide, Int. J. Nanomedicine, vol. 13, pp. 7565-7574, 2018. |
| [18] | G. B. Schober, S. Story, and D. P. Arya. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient, Sci. Rep., vol. 14, no. 1, pp. 1-10, 2024. |
| [19] | P. P. Guimaraes et al. Accelerated in Vivo Delivery Screening, J Control Release. 316: 404-417, 2019. |
| [20] | M. Schlich et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles, Bioeng. Transl. Med., vol. 6, no. 2, pp. 1-16, 2021. |
| [21] | H. J. Jiang, T. C. Underwood, J. G. Bell, S. Ranjan, D. Sasselov, and G. M. Whitesides. Mimicking Lighting-Induced Electrochemistry on the Early Earth, Proc. Natl. Acad. Sci., vol. 120, p. 2017, 2017. |
| [22] | V. P. Zhdanov. Ionizable lipids in bio-inspired nanocarriers, Eur. Biophys. J., vol. 52, no. 1-2, pp. 121-127, 2023. |
| [23] | D. Sun and Z. R. Lu. Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery, Pharm. Res., vol. 40, no. 1, pp. 27-46, 2023. |
| [24] | J. H. Jeon et al. Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo, Int. J. Nanomedicine, vol. Volume 20, no. July, pp. 9389-9405, 2025. |
| [25] | L. Liu et al. PEGylated lipid screening, composition optimization, and structure-activity relationship determination for lipid nanoparticle-mediated mRNA delivery, Nanoscale, vol. 17, no. 18, pp. 11329-11344, 2025. |
| [26] | C. Hald, J. A. Kulkarni, D. Witzigmann, M. Lind, K. Petersson, and J. B. Simonsen. The role of lipid components in lipid nanoparticles for vaccines and gene therapy, Advanced Drug Delivery, Reviews, 188 (2022) 114416. |
| [27] | X. Ge, L. Chen, B. Zhao, and W. Yuan. Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA, Front. Pharmacol., vol. 11, no. January, pp. 1-15, 2021. |
| [28] | J. Suka et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv Drug Deliv Rev. 2016 April 1; 99 (Pt A): 28-51. |
| [29] | L. E. Waggoner, K. F. Miyasaki, and E. J. Kwon. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury, Biomater. Sci., vol. 11, no. 12, pp. 4238-4253, 2023. |
| [30] | P. Ghasemiyeh and S. Mohammadi-Samani. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages, Res. Pharm. Sci., vol. 13, no. 4, pp. 288-303, 2018. |
| [31] | S. Agarwal, S. L. H. Kumar, and R. Garg. Investigative Study on Impact of Solid: Liquid Lipid Ratio and Stabilizer Amount on Some Characteristics of Nanostructure Lipid Carriers of Quetiapine Fumarate. Int. J. Pharm. Investig., vol. 9, no. 2, pp. 47-52, 2019. |
| [32] | M. K. Satapathy et al. Solid lipid nanoparticles (Slns): An advanced drug delivery system targeting brain through bbb, Pharmaceutics, vol. 13, no. 8, pp. 1-36, 2021. |
| [33] | N. Akombaetwa, A. B. Ilangala, L. Thom, P. B. Memvanga, B. A. Witika, and A. B. Buya. Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications, Pharmaceutics, vol. 15, no. 2, pp. 1-47, 2023. |
| [34] | V. A. Duong, T. T. L. Nguyen, and H. J. Maeng. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method, Molecules, vol. 25, no. 20, pp. 1-36, 2020. |
| [35] | Nele V et al. Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies. Advanced Drug Delivery Reviews. Vol. 208, 115291, 2024. |
| [36] | K. T. Sastri, G. V. Radha, S. Pidikiti, and P. Vajjhala. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies, J. Appl. Pharm. Sci., vol. 10, no. 6, pp. 126-141, 2020. |
| [37] | J. E. N. Dolatabadi, H. Valizadeh, and H. Hamishehkar. Solid lipid nanoparticles as efficient drug and gene delivery systems: Recent breakthroughs, Adv. Pharm. Bull., vol. 5, no. 2, pp. 151-159, 2015. |
| [38] | S. Mehrdadi. Lipid-Based Nanoparticles as Oral Drug Delivery Systems: Overcoming Poor Gastrointestinal Absorption and Enhancing Bioavailability of Peptide and Protein Therapeutics, Adv. Pharm. Bull., vol. 14, no. 1, pp. 48-66, 2024. |
| [39] | L. Catenacci et al. Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System, Pharmaceutics, vol. 16, no. 12, 2024. |
| [40] | O. Vasileva, O. Zaborova, B. Shmykov, R. Ivanov, and V. Reshetnikov. Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics, Front. Pharmacol., vol. 15, 2024. |
| [41] | Ahl, P. L. Microfluidic and Turbulent Mixing for mRNA LNP Vaccines. Pharmaceutics, Vol. 17, 1148, 2025 |
| [42] | M. Evers et al. State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery, Small Methods, 2018, 2, 1700375. |
| [43] | P. Tiwary, K. Oswal, R. Varghese, R. V. Peri, and P. Gupta. Solid lipid nanoparticles in cervical cancer: a comprehensive review of a decade of progress and prospects, RSC Pharm., 2025. |
| [44] | I. Chauhan, M. Yasir, M. Verma, and A. P. Singh. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery, Adv. Pharm. Bull., vol. 10, no. 2, pp. 150-165, 2020. |
| [45] | S. Khan, A. Sharma, and V. Jain. An overview of nanostructured lipid carriers and its application in drug delivery through different routes, Adv. Pharm. Bull., vol. 13, no. 3, pp. 446-460, 2023. |
| [46] | A. K. Mahor et al. Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route, J. Nanotechnol., vol. 2023, 2023, |
| [47] | S. Omo-Lamai et al. Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects.,” bioRxiv Prepr. Serv. Biol., 2024. |
| [48] | X. Han et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis,” Nat. Commun., vol. 14, no. 1, 2023. |
| [49] | R. N. Kularatne, R. M. Crist, and S. T. Stern. The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery, Pharmaceuticals, vol. 15, no. 7, 2022. |
| [50] | D. Y. Lee, S. Amirthalingam, C. Lee, A. K. Rajendran, Y. H. Ahn, and N. S. Hwang. Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles, Nanoscale Adv., vol. 5, no. 15, pp. 3834-3856, 2023. |
| [51] | C. Hogarth, K. Arnold, S. Wright, H. Elkateb, S. Rannard, and T. O. McDonald. Navigating the challenges of lipid nanoparticle formulation: the role of unpegylated lipid surfactants in enhancing drug loading and stability, Nanoscale Adv., vol. 6, no. 2, pp. 669-679, 2023. |
| [52] | A. F. Hidayat et al. A Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug Delivery: From Framework to Formulation, Int. J. Nanomedicine, vol. 20, no. July 2025, pp. 8611-8651, 2025. |
| [53] | R. Jeitler et al. On the Structure, Stability, and Cell Uptake of Nanostructured Lipid Carriers for Drug Delivery, Mol. Pharm., vol. 21, no. 7, pp. 3674-3683, 2024. |
| [54] | S. Cui et al. Correlation of the cytotoxic effects of cationic lipids with their headgroups, Toxicol. Res. (Camb)., vol. 7, no. 3, pp. 473-479, 2018. |
| [55] | M. S. Hanafy, H. M. Dao, H. Xu, J. J. Koleng, W. Sakran, and Z. Cui. Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles, Int. J. Pharm. X, vol. 6, no. July, p. 100197, 2023. |
| [56] | K. Syama, Z. J. Jakubek, S. Chen, J. Zaifman, Y. Y. C. Tam, and S. Zou. Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles, Sci. Rep., vol. 12, no. 1, pp. 1-11, 2022. |
| [57] | M. J. Carrasco et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration, Commun. Biol., vol. 4, no. 1, pp. 1-15, 2021. |
| [58] | T. Thanh et al. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines, Vaccines, pp. 1-31, 2021 |
| [59] | G. Prakash, A. Shokr, N. Willemen, S. M. Bashir, S. R. Shin, and S. Hassan. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids, Adv. Drug Deliv. Rev., vol. 184, pp. 1-25, 2022. |
| [60] | K. Suwanpitak, K. Huanbutta, N. Weeranoppanant, P. Sriamornsak, C. Panpipat, and T. Sangnim. Optimization of Lipid-Based Nanoparticles Formulation Loaded with Biological Product Using A Novel Design Vortex Tube Reactor via Flow Chemistry, Int. J. Nanomedicine, vol. 19, pp. 8729-8750, 2024. |
| [61] | E. Atsavapranee et al. Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation, J. Control. Release, vol. 370, pp. 614-625, 2024. |
| [62] | M. C. P. Mendonça, A. Radaic, F. Garcia-Fossa, M. A. da Cruz-Höfling, M. A. R. Vinolo, and M. B. de Jesus. The in vivo toxicological profile of cationic solid lipid nanoparticles, Drug Deliv. Transl. Res., vol. 10, no. 1, pp. 34-42, 2020. |
| [63] | S. V Khairnar, P. Pagare, A. Thakre, A. R. Nambiar, and S. Dyawanapelly. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics 2022, 14, 1886. |
| [64] | E. Subroto, R. Andoyo, and R. Indiarto. Solid Lipid Nanoparticles: Review of the Current Research on Encapsulation and Delivery Systems for Active and Antioxidant Compounds, Antioxidants, vol. 12, no. 3, 2023. |
| [65] | P. Anand, Y. Zhang, S. Patil, and K. Kaur. Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver, J. Med. Chem., vol. 68, no. 7, pp. 6870-6896, 2025. |
| [66] | M. Ripoll et al. Optimal self-assembly of lipid nanoparticles (LNP) in a ring micromixer, Sci. Rep., vol. 12, no. 1, pp. 1-12, 2022. |
| [67] | W. Park et al. Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy, ACS Nano, vol. 19, no. 6, pp. 6412-6425, 2025. |
| [68] | H. Chinthaginjala et al. Nanostructured Lipid Carriers: A Potential Era of Drug Delivery Systems, Indian J. Pharm. Educ. Res., vol. 58, no. 1, pp. 21-33, 2024. |
| [69] | S. Ambati et al. Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles, Commun. Mater., vol. 6, no. 1, 2025. |
| [70] | X. Zhang, Q. Wu, Y. Yu, X. Li, Y. Zhao, and Q. Zheng. Nanocarrier system: An emerging strategy for bioactive peptide delivery, Front. Nutr., vol. 9, no. 1050647, pp. 01-16, 2022. |
| [71] | L. Zhang et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability, npj Vaccines, vol. 8, no. 1, pp. 1-14, 2023. |
| [72] | S. M. Kapnick. The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response, DNA Cell Biol., vol. 41, no. 1, pp. 25-29, 2022. |
| [73] | S. J. Kent et al. Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans, ACS Nano, vol. 18, no. 39, pp. 27077-27089, 2024. |
| [74] | K. Swetha et al. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines, Vaccines, vol. 11, no. 3, 2023. |
| [75] | N. Parvin, T. K. Mandal, and S. W. Joo. The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems, Pharmaceutics, vol. 16, no. 11, 2024. |
| [76] | D. Shinde, G. Basarkar, and C. Upasani. Design and Development of Solid Lipid Nanoparticles Drug Delivery Systems for Prolonged and Targeted Delivery of Fulvestrant, Int. J. Drug Deliv. Technol., vol. 15, no. 1, pp. 196-204, 2025. |
| [77] | S. I. Bukhari et al. Recent progress in lipid nanoparticles for cancer theranostics: Opportunity and challenges, Pharmaceutics, vol. 13, no. 6, 2021. |
| [78] | M. Shafique et al. Formulation development of lipid polymer hybrid nanoparticles of doxorubicin and its in-vitro, in-vivo and computational evaluation, Front. Pharmacol., vol. 14, pp. 1-14, 2023. |
| [79] | A. Mukherjee, A. K. Waters, P. Kalyan, A. S. Achrol, S. Kesari, and V. M. Yenugonda. Lipid-polymer hybrid nanoparticles as a nextgeneration drug delivery platform: State of the art, emerging technologies, and perspectives, Int. J. Nanomedicine, vol. 14, pp. 1937-1952, 2019. |
| [80] | J. A. Kulkarni, D. Witzigmann, S. Chen, P. R. Cullis, and R. Van Der Meel. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics, Acc. Chem. Res., vol. 52, no. 9, pp. 2435-2444, 2019. |
| [81] | A. Mohammadian Farsani et al. Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing, Heliyon, vol. 10, no. 2, p. e24606, 2024. |
| [82] | J. Yan, D. D. Kang, and Y. Dong. Harnessing lipid nanoparticles for efficient CRISPR delivery, Biomater. Sci., vol. 9, no. 18, pp. 6001-6011, 2021. |
| [83] | F. Wu et al. Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components, Small Methods, vol. 2401632, 2025. |
APA Style
Molla, A. (2025). Engineering Lipid Nanoparticles for Enhanced Drug Encapsulation and Release: Current Status and Future Prospective. American Journal of Polymer Science and Technology, 11(2), 15-23. https://doi.org/10.11648/j.ajpst.20251102.11
ACS Style
Molla, A. Engineering Lipid Nanoparticles for Enhanced Drug Encapsulation and Release: Current Status and Future Prospective. Am. J. Polym. Sci. Technol. 2025, 11(2), 15-23. doi: 10.11648/j.ajpst.20251102.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajpst.20251102.11,
author = {Alebachew Molla},
title = {Engineering Lipid Nanoparticles for Enhanced Drug Encapsulation and Release: Current Status and Future Prospective
},
journal = {American Journal of Polymer Science and Technology},
volume = {11},
number = {2},
pages = {15-23},
doi = {10.11648/j.ajpst.20251102.11},
url = {https://doi.org/10.11648/j.ajpst.20251102.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpst.20251102.11},
abstract = {Lipid nanoparticles have emerged as a versatile and effective platform for drug delivery, offering significant advantages such as biocompatibility, scalability, and the ability to encapsulate diverse therapeutic agents including nucleic acids, proteins, and small-molecule drugs. This review comprehensively explores engineering strategies for enhancing drug encapsulation efficiency and achieving controlled release within LNPs. Key formulation components such as ionizable and PEGylated lipids, along with lipid matrix design, play pivotal roles in optimizing nanoparticle stability, payload capacity, and release kinetics. Advances in fabrication methods including microfluidics and solvent mixing techniques have enabled reproducible production of high-quality LNPs tailored for specific therapeutic applications. The critical role of engineered LNPs is exemplified by their success in RNA therapeutics, notably COVID-19 mRNA vaccines, and expanding applications in cancer therapy and protein delivery. The review also highlights challenges like balancing stability and drug loading, minimizing toxicity, and scaling up manufacturing, alongside emerging solutions. Future perspectives emphasize the development of novel lipid materials, hybrid nanocarriers, and integration with personalized medicine and gene editing. These advances position LNPs as a cornerstone for next-generation nanomedicine platforms aimed at safe, efficient, and targeted delivery for a broad spectrum of diseases. The aim of this review is to comprehensively examine the engineering principles and formulation strategies employed to enhance drug encapsulation efficiency and achieve controlled release in lipid nanoparticles.
},
year = {2025}
}
TY - JOUR T1 - Engineering Lipid Nanoparticles for Enhanced Drug Encapsulation and Release: Current Status and Future Prospective AU - Alebachew Molla Y1 - 2025/10/28 PY - 2025 N1 - https://doi.org/10.11648/j.ajpst.20251102.11 DO - 10.11648/j.ajpst.20251102.11 T2 - American Journal of Polymer Science and Technology JF - American Journal of Polymer Science and Technology JO - American Journal of Polymer Science and Technology SP - 15 EP - 23 PB - Science Publishing Group SN - 2575-5986 UR - https://doi.org/10.11648/j.ajpst.20251102.11 AB - Lipid nanoparticles have emerged as a versatile and effective platform for drug delivery, offering significant advantages such as biocompatibility, scalability, and the ability to encapsulate diverse therapeutic agents including nucleic acids, proteins, and small-molecule drugs. This review comprehensively explores engineering strategies for enhancing drug encapsulation efficiency and achieving controlled release within LNPs. Key formulation components such as ionizable and PEGylated lipids, along with lipid matrix design, play pivotal roles in optimizing nanoparticle stability, payload capacity, and release kinetics. Advances in fabrication methods including microfluidics and solvent mixing techniques have enabled reproducible production of high-quality LNPs tailored for specific therapeutic applications. The critical role of engineered LNPs is exemplified by their success in RNA therapeutics, notably COVID-19 mRNA vaccines, and expanding applications in cancer therapy and protein delivery. The review also highlights challenges like balancing stability and drug loading, minimizing toxicity, and scaling up manufacturing, alongside emerging solutions. Future perspectives emphasize the development of novel lipid materials, hybrid nanocarriers, and integration with personalized medicine and gene editing. These advances position LNPs as a cornerstone for next-generation nanomedicine platforms aimed at safe, efficient, and targeted delivery for a broad spectrum of diseases. The aim of this review is to comprehensively examine the engineering principles and formulation strategies employed to enhance drug encapsulation efficiency and achieve controlled release in lipid nanoparticles. VL - 11 IS - 2 ER -
Department of Biotechnology, Wolaita Sodo University, Wolaita, Ethiopia
Information